{"schema_version":"secwatch.filing_event.v1","accession":"0001412408-22-000034","form_type":"8-K","ticker":"PHR","cik":"0001412408","company_name":"Phreesia, Inc.","filed_at":"2022-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.584097+00:00","generated_at":"2026-06-25T05:05:00.323381+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Phreesia Q1 revenue $63.4M (+31% YoY); FY23 Adj. EBITDA guidance raised to -$126M to -$122M","bullets":["Revenue $63.4M vs $48.3M YoY; client count 2,526 (+33% YoY); avg. rev. per client $19,193 (-5% YoY).","Adjusted EBITDA -$30.6M vs +$0.1M YoY; cash $269.2M, down $44.6M from Jan 2022.","FY23 revenue outlook maintained $271M-$275M; Adj. EBITDA outlook raised to -$126M to -$122M from -$154M to -$149M.","Company expects FY23 Adj. EBITDA to be low mark for FY23-FY25, targeting profitability in FY2025.","Life sciences revenue $16.3M; patient payment volume $837M (+19% YoY)."],"urls":{"canonical":"https://secwatch.observer/filing/0001412408-22-000034","json":"https://secwatch.observer/filing/0001412408-22-000034.json","markdown":"https://secwatch.observer/filing/0001412408-22-000034.md","text":"https://secwatch.observer/filing/0001412408-22-000034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412408/000141240822000034/0001412408-22-000034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412408/000141240822000034/phr-20220602.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T05:05:00.323381+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}